Beneficial effects of vitamin D combined with oral iron supplementation in patients with chronic heart failure and iron deficiency (VICTORID-HF TRIAL)

You likely can't join if

• Myocardial infarction or acute coronary syndrome, transient ischemic attack or stroke, coronary artery bypass, percutaneous intervention, or major thoracic or cardiac surgery within the previous 2 months; clinically relevant (severe) non-corrected valvular heart disease, obstructive cardiomyopathy; chronic anemia due to non-correctable causes other than iron deficiency and anemia of chronic disease (e.g., hemoglobinopathies, hematologic malignancies, hemolytic anemia); anemia due to vitamin B12 or acid folic deficiency (recruitment may be re-evaluated at least 6 weeks after the end of vitamin B12 and or folic acid supplementation); history of acquired iron overload; administration of erythropoietin, iron supplementation (either oral or intravenous iron), blood transfusion in the previous 6 weeks or already scheduled for 3 months after recruitment; administration of vitamin D or similar in the 3 months preceding or already scheduled for the 3 months following recruitment; severe bone disease; active infections (C-reactive protein >20 mg/L); clinically significant bleeding; active neoplasm (with exception of basal cell or squamous cell carcinoma of the skin and intraepithelial cervical neoplasia); chronic liver disease (including active hepatitis) and/or alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3x normal limit; immunosuppressive therapy or dialysis; pregnancy or breastfeeding; the subject has a known sensitivity to any of the products that will be administered during the study protocol.